sox2 expression is associated with fgfr fusion genes and predicts favorable outcome in lung squamous cell carcinomas

点击量: 399
ID: 132119
2015
免费 PDF
文章质量与表现指标
综合质量
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI质量评估
未分析
Readership in this journal
Popular

Ranked #7 of 171 articles by views in jurnal tam

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 171 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
摘要
Shanbo Zheng,1,2,* Yunjian Pan,1,2,* Rui Wang,1,2 Yuan Li,2,3 Chao Cheng,1,2 Xuxia Shen,2,3 Bin Li,1,2 Difan Zheng,1,2 Yihua Sun,1,2 Haiquan Chen1,2 1Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China; 3Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China *These authors contributed equally to this work Objectives: SOX2 is a gene that encodes for a transcription factor, which functions as an activator or suppressor of gene transcription. SOX2 amplification and overexpression have been found in various types of tumors and play important roles in cancer cells. The aim of the study was to evaluate SOX2 expression and amplification in lung squamous cell carcinomas (SCCs) and to determine the relationship with main clinicopathologic features, patient prognosis, and common driver mutations. Materials and methods: SOX2 protein levels were measured by immunohistochemistry, while SOX2 copy numbers were measured by fluorescence in situ hybridization in resected samples from 162 Chinese lung SCC patients. All patients were also analyzed for mutations in EGFR, HER2, BRAF, PIK3CA, NFE2L2, and FGFR fusion genes. Clinical characteristics, including age, sex, smoking status, stage, relapse-free survival (RFS), and overall survival (OS), were collected. Results: SOX2 overexpression and amplification were observed in 58.6% and 45.9% of lung SCCs. Lung SCC patients with SOX2 overexpression were significantly associated with absence of malignant tumor family history (P=0.021), FGFR fusion gene (P=0.046), longer RFS (P=0.041), and OS (P=0.025). No correlation was found between SOX2 gene amplification and main clinicopathologic features, patient prognosis, or common driver mutations. Conclusion: SOX2 overexpression and amplification are common in lung SCCs. SOX2 overexpression was associated with FGFR fusion genes and predicted favorable outcome in lung SCCs. The underlying relationship of SOX2 and FGFR still needs further investigation. Keywords: lung squamous cell carcinoma, SOX2 amplification, protein expression, FGFR fusion gene, prognostic marker
参考键
s2015oncotargetssox2 使用此键在稿件中自动引用，同时使用 SciMatic 稿件管理器或论文管理器
作者 ;Zheng S;Pan Y;Wang R;Li Y;Cheng C;Shen X;Li B;Zheng D;Sun Y;Chen H
期刊 jurnal tam
年份 2015
DOI
未找到 DOI
URL
https://www.dovepress.com/sox2-expression-is-associated-with-fgfr-fusion-genes-and-predicts-favo-peer-reviewed-article-OTT
关键词
neoplasms Oncology including cancer and carcinogens tumors

引用

未找到引用。如需添加引用，请联系管理员 info@scimatic.org

评论

暂无评论。成为第一个评论此文章的人。